Management of patients with tuberculosis medication-induced drug reaction with eosinophilia and systemic symptoms
Authors:
- 20 June 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 25 (4) , 237-244
Abstract
Purpose of review: Tuberculosis (TB) incidence is rising globally, and TB medication-associated drug reaction with eosinophilia and systemic symptoms (DRESS) presents a significant clinical challenge, particularly in people living with HIV (PLH). Treatment interruption during active TB, especially with comorbid immunosuppression can be detrimental. This review highlights global variations in management practices and emphasizes the need for a more personalized approach to care. Recent findings: Timely cessation of the suspected medication, supportive care, and topical corticosteroids remain central to DRESS management. However, the routine use of systemic corticosteroids remains debated, as good outcomes from topical steroids alone have been observed, especially in TB/HIV co-infected patients. Efforts to reduce TB treatment interruption have driven interest in the use of shortened TB regimens, sequential additive drug challenge (SADC) with stat dose intravenous corticosteroids to limit positive drug challenge morbidity, and even desensitization protocols. Although not yet widely adopted, these strategies show promise in reintroducing first-line TB drugs, limiting treatment interruptions. Management remains complex, with prolonged hospital stays and high healthcare costs continuing to drive innovation. Summary: The findings support a move towards personalized approaches to TB-DRESS management, with future efforts focused on integrating clinical, genomic, and in-vitro tools to guide risk-stratified reintroduction of TB medications.Keywords
This publication has 43 references indexed in Scilit:
- Drug Rash with Eosinophilia and Systemic Symptoms to Anti-Tuberculosis Therapy: A Retrospective Review of Inpatients at an Academic Medical Centre in the United StatesSkin Health and Disease, 2024
- Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic SymptomsJAMA Dermatology, 2024
- Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part I. Epidemiology, pathogenesis, clinicopathological features, and prognosisJournal of the American Academy of Dermatology, 2023
- Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and managementJournal of the American Academy of Dermatology, 2023
- Recent advances in the treatment of tuberculosisClinical Microbiology and Infection, 2023
- Direct challenges are the gold standard for most antibiotic allergy evaluationsAnnals of Allergy, Asthma & Immunology, 2023
- Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms (DRESS): A monocenter retrospective study of 20 casesAnnales de Dermatologie et de Vénéréologie, 2021
- Efficacy and safety of a four-drug fixed-dose combination regimen versus separate drugs for treatment of pulmonary tuberculosis: a systematic review and meta-analysisBrazilian Journal of Microbiology, 2017
- Immediate-type hypersensitivity reactions due to antituberculosis drugs: a successful readministration protocolAnnals of Allergy, Asthma & Immunology, 2015
- Therapeutic management of DRESS: A retrospective study of 38 casesJournal of the American Academy of Dermatology, 2015